IE 11 is not supported. For an optimal experience visit our site on another browser.

Oxygen Biotherapeutics to Present at Rodman & Renshaw Conference in New York

/ Source: GlobeNewswire

DURHAM, N.C., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that the company will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 14, 2010 at 10:25 AM EDT. The event is being held at The New York Palace Hotel. This presentation will be available via web cast at for a limited time. Company Chief of Staff Kirk Harrington and Chief Financial Officer Michael Jebsen will discuss the Company's strategy, recently commercialized DERMACYTE skin care products and its topical and clinical research and development programs.

Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product called Oxycyte® that is being formulated for both topical and intravenous delivery. In April, the company launched its first cosmetic product, DERMACYTE Oxygen Concentrate and in August it introduced DERMACYTE Eye Oxygenating Complex. In addition, the company is focused on perfluorocarbon-based oxygen carriers for use in traumatic brain injury, decompression sickness, and topical wound healing. More information is available at , and .

The Oxygen Biotherapeutics, Inc. logo is available at

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the plans for the expansion of the DERMACYTE product line and the timing of the introduction of those new products. Matters beyond the company's control could lead to delays in the new product introductions and customer acceptance of these new products. Furthermore, there can be no assurance that such plans will lead to meaningful sales of DERMACYTE or generate any revenue for the company. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release is neither an offer to sell nor a solicitation of an offer to buy any of the Company's securities. No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation, or sale is unlawful.

CONTACT: Oxygen Biotherapeutics, Inc. Ellen Corliss, Vice President, Corporate Communications & Investor Relations (919) 806-4405